The FDA has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

Qfitlia does not replace the missing clotting factor. Rather, it reduces the amount of a protein called antithrombin, leading ...

Alhemo prophylaxis is linked to better quality of life and a lower treatment burden for hemophilia patients without ...

The firm's Innovance Antithrombin assay is used to monitor antithrombin activity levels in hemophilia patients and aid dosing decisions for a routine prophylaxis.

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last three years, the FDA has approved six new drugs for hemophilia. And now the U.

Antithrombin Blood Test from Siemens Healthineers Now FDA Cleared as a Companion Diagnostic for Qfitlia, a Sanofi Hemophilia ...

The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.

Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII (FVIII) or IX (FIX), respectively. Patients with these hemophilias are ...